No Result

View All Result

No products in the cart.

2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑

Home StudyGraphics

#VisualAbstract: Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia

byWinnie LiuandMinjee Kim

November 8, 2023

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract: Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia

Click here to read this study in NEJM.

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Thalidomide reduces recurrent bleeding from small-intestinal angiodysplasia

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

#VisualAbstract GIMEMMA-MMY-3006: Bortezomib, Thalidomide, and Dexamethasone (VTD) Followed By Stem-Cell Transplantation Improves Long-Term Survival Outcomes in Newly Diagnosed Multiple Myeloma (MM)

Provision of HHIV preexposure prophylaxis among adolescents increased from 2018 to 2021

RelatedReports

Study explores effects of daily iron supplementation in 2- to 5-year-olds

Chronic Disease

Thalidomide reduces recurrent bleeding from small-intestinal angiodysplasia

December 5, 2023

StudyGraphics

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

December 18, 2021

The 2MM Team

#VisualAbstract GIMEMMA-MMY-3006: Bortezomib, Thalidomide, and Dexamethasone (VTD) Followed By Stem-Cell Transplantation Improves Long-Term Survival Outcomes in Newly Diagnosed Multiple Myeloma (MM)

December 25, 2020

The 2MM Team

#VisualAbstract CASSIOPEIA Part 1: Bortezomib, Thalidomide, and Dexamethasone with Daratumumab (D-VTd) May Improve Quality of Life Post-Consolidation in Newly Diagnosed, Transplantation-Eligible Multiple Myeloma (MM) Patients

December 24, 2020

Prolonged rest after concussion not linked to improved outcomes

Neuropathologic and psychological changes present in young athletes with repetitive head impacts

Evaluating pediatric sinus antibiotics: effectiveness and safety comparison

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence

Sacituzumab govitecan shows survival benefit in endocrine-resistant hormone-positive metastatic breast cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

#VisualAbstract: Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia

Thalidomide reduces recurrent bleeding from small-intestinal angiodysplasia

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

#VisualAbstract GIMEMMA-MMY-3006: Bortezomib, Thalidomide, and Dexamethasone (VTD) Followed By Stem-Cell Transplantation Improves Long-Term Survival Outcomes in Newly Diagnosed Multiple Myeloma (MM)

Provision of HHIV preexposure prophylaxis among adolescents increased from 2018 to 2021

Neuropathologic and psychological changes present in young athletes with repetitive head impacts

RelatedReports

Thalidomide reduces recurrent bleeding from small-intestinal angiodysplasia

#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma

#VisualAbstract GIMEMMA-MMY-3006: Bortezomib, Thalidomide, and Dexamethasone (VTD) Followed By Stem-Cell Transplantation Improves Long-Term Survival Outcomes in Newly Diagnosed Multiple Myeloma (MM)

#VisualAbstract CASSIOPEIA Part 1: Bortezomib, Thalidomide, and Dexamethasone with Daratumumab (D-VTd) May Improve Quality of Life Post-Consolidation in Newly Diagnosed, Transplantation-Eligible Multiple Myeloma (MM) Patients

Neuropathologic and psychological changes present in young athletes with repetitive head impacts

Evaluating pediatric sinus antibiotics: effectiveness and safety comparison

Sacituzumab govitecan shows survival benefit in endocrine-resistant hormone-positive metastatic breast cancer

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits